Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2016

Open Access 01-12-2016 | Research article

Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis

Authors: Åsa CM Johansson, Sophie Ohlsson, Åsa Pettersson, Anders A. Bengtsson, Daina Selga, Markus Hansson, Thomas Hellmark

Published in: Arthritis Research & Therapy | Issue 1/2016

Login to get access

Abstract

Background

Anti-neutrophil cytoplasmic antibodies associated vasculitides (AAV) is a group of autoimmune diseases, characterized by small vessel inflammation. Phagocytes such as neutrophils and monocytes are the main effector cells found around the inflamed vessel wall. Therefore, we wanted to investigate aspects of function and activation of these cells in patients with AAV.

Methods

Flow cytometry was used to evaluate: the expression of activation markers (CD11c, CD62L, CD177 and C5aR); the number of recently released neutrophils from bone marrow, defined as CD10-D16low cells in peripheral blood; and the capacity of peripheral blood monocytes and polymorphonuclear leukocytes (PMN) to produce reactive oxygen species and to phagocytose opsonized bacteria.

Results

AAV patients (n = 104) showed an increase of CD10-CD16low neutrophils and total PMN in peripheral blood, suggesting a combination of increased bone marrow release and prolonged survival. An increased percentage of AAV PMN expressed CD177 but no other signs of activation were seen. A decreased production of reactive oxygen species was observed in AAV phagocytes, which was associated with disease activity. Moreover, granulocytes from patients with microscopic polyangiitis showed lower oxidative burst capacity compared to patients with granulomatosis with polyangiitis or eosinophilic granulomatosis with polyangiitis. In addition, decreased phagocytosis capacity was seen in PMN and monocytes.

Conclusion

Our results indicate that phagocytes from AAV patients have impaired function, are easily mobilized from bone marrow but are not particularly activated. The association between low reactive oxygen species formation in PMN and disease severity is consistent with findings in other autoimmune diseases and might be considered as a risk factor.
Appendix
Available only for authorised users
Literature
1.
Cartin-Ceba R, Peikert T, Specks U. Pathogenesis of ANCA-associated vasculitis. Curr Rheumatol Rep. 2012;14(6):481–93.CrossRefPubMed
2.
3.
Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170(1):52–64.CrossRefPubMedPubMedCentral
4.
Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.CrossRefPubMedPubMedCentral
5.
Little MA, Smyth CL, Yadav R, Ambrose L, Cook HT, Nourshargh S, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood. 2005;106(6):2050–8.CrossRefPubMed
6.
Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955–63.CrossRefPubMedPubMedCentral
7.
Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol. 2013;8:139–60.CrossRefPubMed
8.
Nowack R, Schwalbe K, Flores-Suarez LF, Yard B, van der Woude FJ. Upregulation of CD14 and CD18 on monocytes In vitro by antineutrophil cytoplasmic autoantibodies. J Am Soc Nephrol. 2000;11(9):1639–46.PubMed
9.
Weidner S, Neupert W, Goppelt-Struebe M, Rupprecht HD. Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. Arthritis Rheum. 2001;44(7):1698–706.CrossRefPubMed
10.
Wikman A, Fagergren A, Forslid J, Jacobson SH, Johansson SG, Lundahl J. Antineutrophil cytoplasmic antibodies induce decreased CD62L expression and enhanced metabolic activity in monocytes. Scand J Immunol. 2003;57(2):179–84.CrossRefPubMed
11.
Kaneko T, Stearns-Kurosawa DJ, Taylor Jr F, Twigg M, Osaki K, Kinasewitz GT, et al. Reduced neutrophil CD10 expression in nonhuman primates and humans after in vivo challenge with E. coli or lipopolysaccharide. Shock. 2003;20(2):130–7.CrossRefPubMed
12.
Orr Y, Taylor JM, Bannon PG, Geczy C, Kritharides L. Circulating CD10-/CD16low neutrophils provide a quantitative index of active bone marrow neutrophil release. Br J Haematol. 2005;131(4):508–19.CrossRefPubMed
13.
Furebring M, Hakansson L, Venge P, Sjolin J. Differential expression of the C5a receptor and complement receptors 1 and 3 after LPS stimulation of neutrophils and monocytes. Scand J Immunol. 2004;60(5):494–9.CrossRefPubMed
14.
Smith CW. Leukocyte-endothelial cell interactions. Semin Hematol. 1993;30(4 Suppl 4):45–53. discussion 54-45.PubMed
15.
Stacker SA, Springer TA. Leukocyte integrin P150,95 (CD11c/CD18) functions as an adhesion molecule binding to a counter-receptor on stimulated endothelium. J Immunol. 1991;146(2):648–55.PubMed
16.
Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87(1):245–313.CrossRefPubMed
17.
Hansson M, Hermodsson S, Brune M, Mellqvist UH, Naredi P, Betten A, et al. Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res. 1999;19(10):1135–44.CrossRefPubMed
18.
Hansson M, Romero A, Thoren F, Hermodsson S, Hellstrand K. Activation of cytotoxic lymphocytes by interferon-alpha: role of oxygen radical-producing mononuclear phagocytes. J Leukoc Biol. 2004;76(6):1207–13.CrossRefPubMed
19.
Holmdahl R, Sareila O, Pizzolla A, Winter S, Hagert C, Jaakkola N, et al. Hydrogen peroxide as an immunological transmitter regulating autoreactive T cells. Antioxid Redox Signal. 2013;18(12):1463–74.CrossRefPubMed
20.
Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, Hellstrand K. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood. 2000;96(5):1961–8.PubMed
21.
Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–7.CrossRefPubMedPubMedCentral
22.
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–32.CrossRefPubMed
23.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.CrossRefPubMed
24.
Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91.PubMed
25.
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–9.CrossRefPubMed
26.
Abdgawad M, Gunnarsson L, Bengtsson AA, Geborek P, Nilsson L, Segelmark M, et al. Elevated neutrophil membrane expression of proteinase 3 is dependent upon CD177 expression. Clin Exp Immunol. 2010;161(1):89–97.PubMedPubMedCentral
27.
Bauer S, Abdgawad M, Gunnarsson L, Segelmark M, Tapper H, Hellmark T. Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. J Leukoc Biol. 2007;81(2):458–64.CrossRefPubMed
28.
von Vietinghoff S, Eulenberg C, Wellner M, Luft FC, Kettritz R. Neutrophil surface presentation of the anti-neutrophil cytoplasmic antibody-antigen proteinase 3 depends on N-terminal processing. Clin Exp Immunol. 2008;152(3):508–16.CrossRef
29.
Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol. 1996;156(1):42–7.PubMed
30.
Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet’s disease. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S19–24.PubMed
31.
Mossberg N, Andersen O, Nilsson S, Dahlgren C, Hellstrand K, Lindh M, et al. Oxygen radical production and severity of the Guillain–Barre syndrome. J Neuroimmunol. 2007;192(1-2):186–91.CrossRefPubMed
32.
Mossberg N, Movitz C, Hellstrand K, Bergstrom T, Nilsson S, Andersen O. Oxygen radical production in leukocytes and disease severity in multiple sclerosis. J Neuroimmunol. 2009;213(1-2):131–4.CrossRefPubMed
33.
Izzedine H, Cacoub P, Launay-Vacher V, Bagnis C, Deray G. Lymphopenia in Wegener’s granulomatosis. A new clinical activity index? Nephron. 2002;92(2):466–71.CrossRefPubMed
34.
Fauci AS, Dale DC, Wolff SM. Cyclophosphamide and lymphocyte subpopulations in Wegener’s granulomatosis. Arthritis Rheum. 1974;17(4):355–61.CrossRefPubMed
35.
Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest. 1987;79(4):1082–90.CrossRefPubMedPubMedCentral
36.
Abdgawad M, Pettersson A, Gunnarsson L, Bengtsson AA, Geborek P, Nilsson L, et al. Decreased neutrophil apoptosis in quiescent ANCA-associated systemic vasculitis. PLoS One. 2012;7(3):e32439.CrossRefPubMedPubMedCentral
37.
Bengtsson AA, Pettersson A, Wichert S, Gullstrand B, Hansson M, Hellmark T, et al. Low production of reactive oxygen species in granulocytes is associated with organ damage in systemic lupus erythematosus. Arthritis Res Ther. 2014;16(3):R120.CrossRefPubMedPubMedCentral
38.
39.
Taylor NJ, Nishtala A, Manakkat Vijay GK, Abeles RD, Auzinger G, Bernal W, et al. Circulating neutrophil dysfunction in acute liver failure. Hepatology. 2013;57(3):1142–52.CrossRefPubMed
40.
Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–23.CrossRefPubMedPubMedCentral
41.
Fukushima K, Ando M, Ito K, Suga M, Araki S. Stimulus- and cumulative dose-dependent inhibition of O2- production by polymorphonuclear leukocytes of patients receiving corticosteroids. J Clin Lab Immunol. 1990;33(3):117–23.PubMed
42.
Ohlsson SM, Ohlsson S, Soderberg D, Gunnarsson L, Pettersson A, Segelmark M, et al. Neutrophils from vasculitis patients exhibit an increased propensity for activation by anti-neutrophil cytoplasmic antibodies. Clin Exp Immunol. 2014;176(3):363–72.CrossRefPubMedPubMedCentral
43.
El-Benna J, Dang PM, Gougerot-Pocidalo MA. Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol. 2008;30(3):279–89.CrossRefPubMed
Metadata
Title
Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis
Authors
Åsa CM Johansson
Sophie Ohlsson
Åsa Pettersson
Anders A. Bengtsson
Daina Selga
Markus Hansson
Thomas Hellmark
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2016
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-016-0994-1

Other articles of this Issue 1/2016

Arthritis Research & Therapy 1/2016 Go to the issue

Research article

Long non-coding RNA expression profile in minor salivary gland of primary Sjögren’s syndrome

Research article

H3K27me3 demethylases regulate in vitro chondrogenesis and chondrocyte activity in osteoarthritis

Research article

Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty

Research article

Abdominal obesity, gender and the risk of rheumatoid arthritis – a nested case–control study

Research article

p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis

Research article

JAK3-STAT pathway blocking benefits in experimental lupus nephritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits